Gene Therapy Offers Glimmer of Hope for Intractable Epilepsy

LEXINGTON, MA – June 19, 2026 – For the hundreds of thousands of people living with epilepsy that defies conventional treatment, the daily reality is a draining cycle of unpredictable seizures and debilitating side effects. Today, a glimmer of hope emerged from the frontier of genomic medicine. Gene therapy leader uniQure announced promising preliminary data from its Phase I/IIa trial for AMT-260, a novel, one-time treatment for refractory mesial temporal lobe epilepsy (MTLE), the most common and treatment-resistant form of focal epilepsy.

The initial results, presented at the Epilepsy Foundation Pipeline Conference, suggest the therapy is not only well-tolerated but may also significantly reduce seizure frequency in some patients, offering a potential breakthrough for a community desperately in need of new options.

The Promise and the Data

The GenTLE clinical trial is the first-in-human study of AMT-260, and the initial data comes from the first, low-dose cohort of six patients. Six months after receiving a single, targeted infusion of the gene therapy, the results are a study in contrasts, yet undeniably encouraging.

Three of the six patients experienced a meaningful reduction in disabling seizures, with declines ranging from a remarkable 79% to a complete 100% cessation during the fourth through sixth months of follow-up. For these individuals, the data hints at a life-altering impact. The other three patients in the cohort saw variable results, ranging from a 33% decrease in seizures to a 36% increase compared to their baseline, underscoring the complexity of the disease and the early nature of the research.

Crucially for a first-in-human trial involving direct brain administration, the safety profile appears favorable. uniQure reported no serious adverse events related to either the gene therapy or the surgical procedure used to deliver it. The most common side effect was a mild or moderate headache, and no patients required immunosuppression, a common concern with AAV-based therapies.

“While patient responses have varied, we believe the data generated to date provide preliminary evidence of biological activity of AMT-260,” said Walid Abi-Saab, M.D., chief medical officer of uniQure, in a statement. “Although these findings are based on a limited number of patients and require longer follow-up, the favorable tolerability profile and observed responses support continued evaluation of AMT-260.”

A New Frontier in Neurological Treatment

Unlike daily anti-seizure medications that offer systemic, often temporary relief, AMT-260 represents a paradigm shift. It is designed to be a one-time, disease-modifying treatment that tackles the biological root of the seizures. The therapy uses a harmless adeno-associated virus (AAV) as a delivery vehicle to introduce two engineered microRNAs directly into the affected brain tissue. These microRNAs are designed to silence the GRIK2 gene, which produces the GluK2 protein—a key component of a glutamate receptor believed to trigger the hyperexcitability and aberrant signaling that leads to seizures in MTLE.

This highly targeted approach, enabled by the company's proprietary miQURE® gene silencing platform, aims to restore normal function only in the seizure-generating cells, leaving healthy brain tissue untouched. This level of precision stands in stark contrast to existing treatments. For patients with refractory MTLE, current options are often limited to invasive brain surgery with significant risks, or palliative neurostimulation devices. AMT-260 offers the potential for a less destructive, more targeted biological fix.

This ambitious neurological program builds on uniQure’s established expertise. The company is behind Hemgenix, the world's first approved gene therapy for hemophilia B, a historic achievement that validated its research platform. By applying its knowledge to the complexities of the central nervous system, uniQure is pushing into one of the most challenging and promising areas of modern medicine.

Cautious Optimism on the Long Road Ahead

While the market has responded with enthusiasm—uniQure's stock surged over 60% following the news—experts in the field urge a more measured perspective. The results, while promising, are from a very small group of six patients over a short timeframe. The variability in patient response highlights a key challenge in epilepsy treatment: the disease's inherent heterogeneity.

“These are encouraging first steps, but we are at the beginning of a very long and complex journey. The brain is not an easy target,” noted one neuro-geneticist not involved with the study. “Phase I trials are about safety first and foremost, and these signals of efficacy are a welcome bonus. But we cannot draw firm conclusions until we see data from more patients, at higher doses, and over several years.”

The path forward for uniQure is clear but demanding. Enrollment is already underway for a second cohort of six patients who will receive a threefold higher dose of AMT-260. The performance of this group will be critical in determining if a stronger dose can produce more consistent and profound seizure reduction without compromising the therapy’s favorable safety profile. The company expects to complete enrollment for this cohort by mid-2026 and present updated results in the first half of 2027.

The High Stakes of Biotech Innovation

The dramatic investor response to this early data underscores the high-stakes nature of the biotechnology industry. It provides a welcome boost for uniQure, which recently experienced the sector's characteristic volatility with its Huntington's disease program. The journey of a single biotech company's stock often mirrors the rollercoaster of clinical development, swinging wildly on regulatory feedback and trial results.

This announcement firmly places uniQure at the forefront of a growing race to develop gene therapies for neurological disorders. Competitors are also advancing their own AAV-based and antisense oligonucleotide (ASO) therapies for various forms of epilepsy. However, today's news provides a tangible piece of evidence that gene silencing in the brain is a viable strategy for this devastating condition.

For the nearly 200,000 Americans with refractory MTLE, this early data is more than just a stock-moving event; it is a critical step toward a future where their condition might not just be managed, but potentially resolved with a single treatment. The entire medical community will be watching closely as uniQure gathers more data, hoping this initial glimmer of hope brightens into a new standard of care.